Ten prepubertal boys, aged 6-12 years, presenting with unilateral or bilateral cryptorchidism were treated with a single i.m. injection of 100 micrograms of synthetic LHRH. In addition to the clinical effect, pituitary responsiveness was studied. Immunoreactive FSH and LH in serum were measured by radioimmunoassay. One week after the treatment a complete descent of testes occurred in the four oldest patients. In another four patients, a clear-cut improvement in their condition was seen, and, in two patients, no effect was observed. In nine patients, a significant (p less than 0.001) rise in serum FSH and LH levels was observed. In one patient, serum gonadotropin levels remained unchanged. There was no correlation between the clinical effect and pituitary responsiveness. It was concluded that i.m. administration of LHRH offers advantages over the paranasal route since the dose required for a good effect appears to be considerably lower.

Age Factors↗

PubMedDate not supplied

Urinary, plasma and adrenal tissue steroids in a male patient with Cushing's syndrome due to adrenal carcinoma.

The dynamics of urinary and plasma steroids (CPB and RIA) were simultaneously studied in a 36-yr-man with Cushing's syndrome due to adrenal carcinoma. The markedly increased basal excretion of 5-pregnenetriol, PG, PGT, DHA, THS and corticosteroids with nonsignificant changes during the endocrine tests decreased to normal levels after tumour removal. The basal low level of plasma testosterone, with nonsignificant changes during the endocrine tests, rose progressively after surgery. The steroid content of adrenal carcinoma tissue determined by CPB and RIA after LH-20-Sephadex CC separation revealed important proportion of unconjugated 17-OH-P.

Adrenal Gland Neoplasms↗

PubMedDate not supplied

Placebo-controlled cross-over study of effects of Org OD 14 in menopausal women.

A double-blind cross-over study with Org OD 14 and placebo was performed in 82 menopausal patients presenting with hot flushes and associated symptoms. Patients were randomly allocated to Org OD 14 or placebo as first treatment, and switched to placebo or Org OD 14 as second treatment. Each treatment period lasted for 16 weeks; no wash-out period was introduced. Tablets containing 2.5 mg of Org OD 14 or matched placebo tablets were supplied. Data on the following variables were obtained and analysed by the non-parametric randomization test for paired observations: hot flushes, sweating, dizziness, palpitations, fatiguability, headache, sleeplessness, irritability, breathlessness, backache and loss of libido and, in 16 patients, on circulating levels of FSH, LH, PRL, T3, T4, cortisol (F), SHBG, TBG and CBG. Twenty patients (13 placebo, 7 Org OD 14) withdrew, because their symptoms did not improve and one patient withdrew for reasons unrelated to treatment, so that 61 patients completed the study. The data demonstrated a good clinical effect and statistically significant differences in favour of Org OD 14 for hot flushes and a number of associated symptoms. Many patients reported on a general feeling of well being and a mood-elevating effect following Org OD 14. Org OD 14 significantly suppressed FSH and LH levels, while those of PRL remained unchanged. Although there was slight suppression of TBG and T4 which attained statistical significance, there was no influence on the most important parameter, T3. SHBG levels were slightly suppressed, whereas F and CBG levels were unaffected.

Climacteric↗

PubMedDate not supplied

Placebo-controlled study of effects of epimestrol on the pituitary-testicular axis in normal men.

Twenty healthy male volunteers were randomly allocated to the treatment with either 15 mg/day of epimestrol or placebo for 10 days. The plasma levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), oestradiol (E2) and prolactin (PRL) were measured before, during and 4 days after the medication by radioimmunoassays. Data were statistically evaluated by means of an analysis of covariance. Circulating LH and FSH, and also T and E2 significantly increased in the epimestrol treated subjects. In the placebo treated subjects no significant changes in the plasma hormone levels were observed. There were no significant changes in the plasma levels of PRL in either group.

Administration, Oral↗

PubMedDate not supplied

Ovulation-inhibiting properties of Org OD 14.

Org OD 14 has recently been shown to be an interesting new steroid for the treatment of menopausal women. In view of the importance of treatment of perimenopausal women, in whom ovulation might occur, the aim of the present study was to assess whether or not Org OD 14, administered orally in a daily dose of 2.5 mg for 21 days, inhibits ovulation. Sixteen healthy female volunteers, aged 20-34 years and with established ovulatory cycles, were studied during a control cycle and a treatment cycle. Daily measurements of the plasma levels of FSH, LH, E2, P and PRL were made. Endometrial specimens were obtained from nine of the volunteers between 23rd and 25th day of both cycles. The criteria for an ovulatory cycle were: (1) mid-cycle FSH, LH and E2 peaks; (2) criteria (1) followed by a rise in the P levels of greater than 10 ng/ml; (3) a luteal phase of at least 12 days; (4) biphasic behaviour of E2; and, (5) secretory endometrium on days 23-25 of the cycle. All control cycles were ovulatory. During the treatment the mid-cycle FSH, LH and E2 peaks disappeared, and P levels remained very low. PRL levels showed an occasional moderate rise in some of the volunteers. Endometrial specimens showed a secretory pattern during the control cycle, and different degrees of proliferation during the treatment cycle in all nine volunteers. It was concluded that Org OD 14 inhibited ovulation in all 16 volunteers.

Adult↗

PubMedDate not supplied

[Failure of disodium cromoglycate in the treatment of 17 patients with chronic inflammatory diseases of the intestine. An occasion to review the pathogenetic problems of ulcerative rectocolitis and Crohn's disease].

Explore the source record for details and available documents.

Adolescent↗

PubMedDate not supplied

A comparative study of clomiphene and epimestrol on plasma progesterone, CBG, TBG and SHBG, and salivary progesterone levels.

The plasma levels of CBG, TBG, SHBG and progesterone, and salivary progesterone levels were measured in eight young ovulatory volunteers. After the control cycle four subjects received 50 mg/day of Clomiphene from days 5 to 9 of the first treatment cycle, and 10 mg/day of Epimestrol from days 5 to 15 of the second treatment cycle. The other four subjects received the treatments in reverse order. Between the two treatments there was one cycle without medication as a "wash-out" period. Plasma and saliva samples were obtained on days +6, +8 and +10 (day of LH peak was denoted by 0), always between 08.00 and 09.00 h. Statistical evaluation was done by means of an analysis of variance (ANOVA), and correlation coefficients were also calculated. Evaluation of data on effects of Clomiphene and Epimestrol on the plasma levels of CBG and salivary progesterone showed that Clomiphene induced a highly significant rise (p less than 0.001) in the CBG levels and decrease (p less than 0.001) in salivary progesterone levels, while no changes were seen following administration of Epimestrol. Both Clomiphene and Epimestrol treatments led towards higher plasma progesterone levels, those following Clomiphene administration being higher. Neither treatment induced significant changes in TBG or SHBG levels. It is concluded that Clomiphene induces significant elevations of CBG and decrease in salivary progesterone, which is thought to reflect the free progesterone fraction and may have significance in relation to a discrepancy between the ovulation and pregnancy rates following Clomiphene therapy.

Adult↗

PubMedDate not supplied

Concealed, bigeminal, interpolated A-V junctional (extrasystolic or parasystolic) complexes.

Explore the source record for details and available documents.

Adult↗

PubMedDate not supplied

Lack of suppression of increased circulating prolactin by 2-hydroxyestrone.

To study the effect of 2-hydroxyestrone (2-OHE1) on circulating prolactin (PRL) in a hyperprolactinaemic state, seven anovulatory women with hyperprolactinaemia were given a 2-OHE1 infusion at a rate of 80 microgram/h for 3 h following a control infusion. Plasma samples for PRL determination were obtained at 30-minute intervals for 6h. No changes in PRL levels were observed during the 2-OHE1 infusion as compared with the control period. It was concluded under conditions of the present experiment that 2-OHE1 does not suppress circulating PRL in hyperprolactinaemic anovulatory women.

Adult↗

PubMedDate not supplied

Evaluation of the clinical electrophysiological effects of antianginal drugs without specific antiarrhythmic properties.

The authors have studied the electrophysiological effects of four antianginal drugs: oxyfedrine, nifedipine, dipyridamole and carbochromene. These drugs demonstrated different and sometimes contrasting effects on sinus node function, atrial refractoriness and atrioventricular conduction. These effects may constitute an indication or a contraindication in different clinical pictures and should be considered in the choice of treatment of patients with coronary artery disease.

Angina Pectoris↗

PubMedDate not supplied

Correlation between incremental changes of oestradiol-17 beta and prolactin during the menstrual cycle by means of multiple plasma sampling.

Incremental changes of circulating oestradiol-17 beta (E2) and prolactin (PRL) at midcycle and in the luteal phase were studied in 7 healthy young women by means of multiple plasma sampling over a longer period of time. The mean E2 and PRL levels were significantly higher at both times of assessment than in the follicular phase (p less than 0.001). Rapid fluctuations of both E2 and PRL levels were observed; amplitude of E2 fluctuations was increased at higher mean E2 plasma levels. Regression analysis showed a significant correlation (r = 0.62; p less than 0.01) between the incremental changes of E2 and PRL levels at midcycle and in the luteal phase. The present data shows that changes in the plasma levels of E2, and perhaps in the amplitude of the fluctuations, play a crucial role in the regulation of PRL secretion and release during the normal menstrual cycle.

Adult↗

PubMedDate not supplied

Fluctuations in plasma oestradiol levels in normal men.

Plasma levels of oestradiol were measured in blood samples obtained from 6 normal men every 12 minutes for two 4-hour periods: between 08.00 and 12.00h and between 18.00 and 22.00h. Circulating oestradiol was measured by radioimmunoassay after chromatographic separation on microcolumns of Sephadex LH-20. Mean values of oestradiol concentrations and coefficients of variation for two 4-hour periods were calculated for each subject and for the whole group. Data were statistically evaluated by means of the Wilcoxon signed-rank test. Rapid fluctuations in plasma oestradiol levels were observed in all subjects. The pattern of the fluctuations was found to be irregular and different in each subject. The mean concentration and coefficient of variation were significantly (p less than 0.05) higher in the morning, suggesting the possibility of a circadian rhythm in the secretion of oestradiol in men.

Circadian Rhythm↗